Department of Cell Biology and Physiology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.
Division of Hematology and Oncology, Department of Medicine, School of Medicine, Washington University School in St. Louis, St. Louis, Missouri.
Cancer Res. 2021 Sep 1;81(17):4499-4513. doi: 10.1158/0008-5472.CAN-20-4016. Epub 2021 Jul 2.
Nonsense-mediated RNA decay (NMD) is recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTC) for degradation, however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system to accurately measure NMD activity in individual cells. A genome-wide CRISPR-Cas9 knockout screen using this reporter system identified novel NMD-promoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, cells with mutations in the spliceosome genes and , which are commonly found in myelodysplastic syndrome (MDS) and cancers, have overall attenuated NMD activity. Compared with wild-type (WT) cells, SF3B1- and U2AF1-mutant cells were more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage, and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition was rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, these findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel synthetic lethal strategy for the treatment of MDS and cancers with spliceosome mutations. SIGNIFICANCE: This study has developed a novel NMD reporter system and identified a potential therapeutic approach of targeting the NMD pathway to treat cancer with spliceosome gene mutations.
无意义介导的 RNA 衰减(NMD)被认为是一种 RNA 监测途径,可针对具有过早翻译终止密码子(PTC)的异常 mRNA 进行降解,然而,其分子机制及其在健康和疾病中的作用仍不完全清楚。在这项研究中,我们开发了一种新的报告系统,可以准确测量单个细胞中的 NMD 活性。使用该报告系统的全基因组 CRISPR-Cas9 敲除筛选鉴定了新的 NMD 促进因子,包括 SF3B 复合物的多个成分和其他 U2 剪接体因子。有趣的是,具有剪接体基因 和 突变的细胞(在骨髓增生异常综合征(MDS)和癌症中常见)的总体 NMD 活性减弱。与野生型(WT)细胞相比,SF3B1 和 U2AF1 突变细胞对 NMD 抑制更敏感,这种表型伴随着 DNA 复制受阻、DNA 损伤和染色体不稳定的增加。值得注意的是,通过表达 RNase H1 (可去除基因组中的 R-环)可挽救剪接体突变细胞对 NMD 抑制的敏感性。总之,这些发现揭示了 NMD 和 RNA 剪接之间的功能相互作用,并为治疗具有剪接体突变的 MDS 和癌症提供了一种新的合成致死策略。
本研究开发了一种新的 NMD 报告系统,并确定了一种靶向 NMD 途径的潜在治疗方法,以治疗具有剪接体基因突变的癌症。